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Conclusion: Challenges for the Future
by D. Warner North
The title "Challenges for the Future" implies the challenge to summarize a very complex meeting. Of
necessity, Iwillpresentapersonalimpression.Myinterestisinriskassessment,whichIdefineasaprocessfor
summarizing science in support of decision making. Risk assessment is sometimes regarded as arcane
numerology, a rigid process of computing risk numbers in which much available science is unused. I am a
strong advocate forthe broader definition ofrisk assessment. It is encouraging to learn how much science is
becoming available for use in risk assessment for gasoline, its components, and alternative fuels.
The Decision Context
Atthebeginningofthesymposium,JohnGrahamnoted
that we are making multibillion dollar decisions on the
basis ofthe studies presented. How do we summarize the
science for a multibillion dollar decision? Carefully, with
the participation and critical review of the best people
available. This is what we have been doing. I want to
extend my complements and thanks to the sponsors and
the symposium planning committee. Much new scientific
information waspresented, andthe discussants, panelists,
and audience havereactedtothisinformationwith percep-
tive questions, challenges, and suggestions for further
analysis and research.
I do not have a large part of my professional life
committed to the topic ofthis symposium. Thatputs me at
a disadvantage in terms ofthe depth ofmy knowledge on
many of the details. The symposium planning committee
asked me to give this wrap-up talk in the hope that I can
provide a perspective to help integrate all that we have
heard overthepast4daysandto assesstheimplications of
this material. I hope I can stimulate your thinking about
the big issues: what science can tell us now about the
healtheffects ofgasoline;whatsciencemightbeabletotell
us in the future, given the expenditures that are made for
further research, data acquisition, and analysis; how sci-
ence can be summarized and communicated to those
responsible for decision making; and how ourinstitutions,
procedures, and attitudes might evolve to facilitate better
decision making.
Gasoline is perhaps the most familiar "chemical" for
citizens of industrialized societies. Some of our largest
industrial firms refine gasoline from petroleum and mar-
ket it to hundreds ofmillions of consumers whose mobile
lifestyle depends on it. So as manufacturers, vendors, and
consumers, we have many decades of experience with
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gasoline. We have familiarity, but also fear and mistrust.
Many of you know far better than I how the public feels
about oil companies and government regulatory agencies.
Asseveral ofyouhavepointed out,riskcommunicationis a
difficult business. The National Academy of Sciences
report "Improving Risk Communication" indicates that
the best way to make progress is assiduous attention to
detail in the process ofbuilding trust.
Likewise, many ofyoumayunderstandbetterthan I do
howstronglythepublicfeelsaboutincreasesinthepriceof
gasoline. And how the public feels about reducing smog:
the ozone and other pollutants formed from reactive
hydrocarbon emissions and oxides of nitrogen. There is
alsotheinternational competitionissue: oilproductionand
refining are moving offshore because of the regulatory
environment. A lot of money and jobs are at stake. And
then there is the greenhouse issue, which is linked to
energy efficiency. How does it all fit together?
The challenge to all of us is to increase the extent to
which decisions reflect an understanding of science. I
thinkthisimplieswe must do abetterjob ofeducating the
publicand ourleadersinboththepublicandprivatesector.
It is an awesome challenge. I submit that meeting the
challenge will require that a large number of us become
risk communicators as well as risk assessors and scien-
tists. This meeting has been an important milestone. But
to impact the decisions, the messages from this meeting
need to reach a wide audience.
Let me now turn from the decision context to my
summaryofthemeeting, ofwhatwassaid, andthetopics I
think deserve more exploration in future meetings ofthis
type. First,letme statemyconclusion onthehealtheffects
ofgasoline.Wehavedecades ofexperiencewithgasolinein
its present form. My impression is that the health effects
aremodest,butthere are some. Highdoses ofgasoline are
clearlydangerous.Atthe sametime,thedataandanalyses
presented at this conference suggest that the health risk
tothepublicfromgasolineproperlyusedin motorvehicles
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risks couldbe larger.Whatare thepotential serious risks?
And how can we facilitate careful assessment of these
risks as input to the decision process?
Exposure
The symposium began with a session on exposure. Paul
Lioy stated in summarizing the conclusions from last
year's gasoline exposure workshop: "There is a need for
realistic exposure scenarios, and for understanding the
uncertainties." This theme has been echoed in various
forms throughout the meeting. Gerry Akland noted the
need to look at microenvironments and human activity
patterns. Jack Moore introduced the afternoon session by
tellingus that"Exposure data canbethe criteriabywhich
you decide whether you need toxicity data."
Last year's workshop and this year's exposure session
illustrated that better exposure data can be obtained. We
can get measurements of the levels and the time at self-
service pumps forconsumers and atfull service pumps for
occupational exposure. I heard a lot of reinforcement for
the value ofold-fashioned industrial hygiene: break expo-
sure situations down into tasks; then use modeling, mea-
surements, extrapolation, and data in old files-whatever
works. The data can always be made better for a price.
What level ofaccuracy do we need? Roger McClellan and
Peter Rombout stressed the interaction ofusing exposure
and toxicity information together in an iterative risk
assessment process that helps us to understand where
additional data are most needed.
Noncancer End Points of Gasoline
and Key Components
The literature reviews presented at this symposium on
acute toxicity, neurotoxicity, and developmental and
reproductive toxicity are clearly important contributions
toward understanding the potential problems and plan-
ningneededresearch. Butwhatdo these datatellus about
impacts onpublic health? We need to look at abroad range
of exposure scenarios.
The potential for aspiration pneumonia for inhaling a
small amount ofgasoline liquid impressed me. The poten-
tial for acute toxicity as the result of human exposure is
clearlyhigh. Ingestion ofateaspoon ofmethanol can kill a
child or cause blindness in an adult. It seems clear to me
that we should look carefully at end points and exposures
involving misuse, spills, accidents, and contamination
rather than limiting risk assessments to inhalation expo-
sure under routine conditions.
Lead was mentioned in passing; it is still used in gas-
oline in Europe and in most of the world, but yet no one
usedlead asanexample oftheidentificationandcharacter-
ization ofthehealthimpacts ofagasoline constituent, past
orpresent. Are there more compounds like lead outthere?
Not too many years ago, EPA made a decision to remove
lead from gasoline. We have since observed amajorreduc-
tion in the blood lead levels ofchildren. We have reason to
believe that elevated blood lead levels translate into subtle
effects on the nervous system. Would EPA have required
the leadphase-outifithad notbeenfortheimpacts oflead
in poisoning catalytic converters? Mexico is now taking
decisions to remove lead from gasoline. Other countries
may be doing so as well.
We have not yet found a new "bad actor" comparable to
lead-some effect indicating that a key gasoline compo-
nentneeds to be reduced frompresent orprojected future
levels. But we have identified benzene, and butadiene is
also under suspicion.
We need more focus on mixtures and synergisms. For
example, n-hexane is potentially harmful as a pure sub-
stance at high exposure levels; but as a component of
gasoline, the risk may be reduced, because the enzymes
that form the damaging metabolites from n-hexane get
distributed amongmanyothercomponentsinthemixture.
We need to spend more effort on these mixture issues and
to share our understanding of these issues with the reg-
ulatory agencies and the public.
Carcinogenicity of Gasoline
As a member of the Environmental Health Committee
of EPA's Science Advisory Board, I participated in a
review of the bioassay results from inhalation of fully
vaporized unleaded gasoline shortly after these bioassay
results became available to EPA. Several of us on the
Committee calculated upper bound cancer risk from the
exposure information and cancer potency as computed
fromthebioassayresults. I recall thatmy calculation gave
6 x 10-5, and I was awed by the magnitude of the risk
management issue that this result posed for EPA. But at
that time, information on the mechanism ofaction for the
male kidney tumors in the male rat was beginning to
emerge from the research by James Swenberg and his
colleagues at the Chemical Industry Institute of Toxicol-
ogy (CIIT). This research and the interpretation of the
research results by EPA have set an important precedent
forthe use ofmechanistic information in risk assessment.
While some uncertainties remain, many in the scientific
communitynowthinkthatenoughisknownaboutthemale
rat kidney response from fully vaporized unleaded gas-
oline to conclude that this animal tumor response is not
predictive of a human cancer risk.
What aboutthe otherresult from the bioassay, the liver
tumors in female mice? Little has been done on this issue,
and furtherinvestigation is needed. An interesting poster
by Judy MacGregor and colleagues indicates the pos-
sibility of a hormonal mechanism for these tumors.
Epidemiology Studies
It is gratifying to see the epidemiology on refinery and
distribution workers. We have run a massive human
experiment, at the parts per million level, in the occupa-
tional group. I offer as a simplified conclusion thatthere is
no large effect in causing human cancer. There is strong
evidence for an elevated riskfor acute myeloid leukemiain
groups occupationally exposed many decades ago to ben-
zene, and there is substantial but perhaps not conclusive
evidence that benzene causes elevated incidence of other
leukemias and myeloma as well.
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If there is an elevated incidence of kidney or other
cancers fromthe occupational exposure, itis smallenough
tobe hard tofind.As anonepidemiologist, I amimpressed
withthedifficultyofinterpretation, giventhepopulation of
healthy workers, lack of smoking data, and confounding
effects of lifestyle (smoking, drinking, and disease mis-
classification problems).
I return to the theme of exposure scenarios. As an
example, truckdriverswhoworegasoline-soaked clothing
for years inside a confined space should be good candi-
dates for acute myeloid leukemia. This hypothesis seems
wellworth continuedinvestigationwith case-control stud-
ies. My suspicion is that if you find an elevated leukemia
incidence, it will be associated with very high exposure
levels well above today's occupational limits. Then we will
need to ask what the implications are for today's occupa-
tional and ambient exposure levels.
Epidemiological data may not resolve the extent ofthe
risk at low doses, and uncertainties will remain about the
extent to which gasoline components cause various health
endpoints. Itisusefulwheninformedexpertjudgmentcan
be summarized in the form of a quantitative statement
abouttheuncertainty. BernardGoldstein gave anexample
when he told us that in hisjudgment the probability that
benzene causesmyelomais greaterthan50%. Thattypeof
statement conveys important information to those with
risk management responsibility. Similarly, it is good to
hear the epidemiologists discussing the need to include
judgments on biological plausibility and not restricting
themselves to adiscussionofthep-values. PhilipEnterline
shared with us his classroom illustration, a medical deci-
sion situation involving a close relative, where an experi-
mental treatment shows an expected improvement that is
not statisticallysignificant. Inthe scientific context,we do
not yet meet the usual standard for concluding that the
experimental treatment is effective. But in the decision
context, theexperimental treatmentmaybethebestalter-
native available for the patient. Epidemiological data are
important in the public health decision context even if
statistical significance has not been obtained.
The presentations and discussion on formaldehyde,
butadiene, andbenzene shows the progressbeingmade in
risk assessment. A major theme is the importance of




Roger McClellan stressed that the goal of protecting
public health motivates increased emphasis on the steps
beyond hazard identification in the risk assessment para-
digm from the 1983 National Academy Redbook. These
steps are dose- or exposure-response assessment, expo-
sure assessment, and risk characterization. As Jack
Moorenoted,theinformationfromoccupationalexposures
isinthepartspermillion rangewhilepublicexposures are
in the parts per billion range. What is the shape of the
dose-response curve, and what are the implications of a
better understanding ofmechanism for the extrapolation
from parts per million to parts per billion? An increased
understanding of what is biologically plausible may be
critical for public health risk management.
Formaldehyde and butadiene provide examples of pro-
gress on developing mechanistic understanding that can
be used in exposure-response assessment. The bioassay
dataforformaldehyde arehighlynonlinear.Amechanistic
understanding for these data is being sought in the
researchwork atCIIT. LindaBirnbaum's presentation on
butadiene summarized the progress beingmade in under-
standingmetabolic differences between species. Both case
studies illustrate how pharmacokinetic and phar-
macodynamic approaches are being applied to model the
relationship between exposure and response.
The third case study, on benzene, also stressed the
importance of mechanistic information. Dennis Pausten-
bach concluded his presentation with the opinion that
"Only better mechanistic data incorporated into a phys-
iologically based pharmacokinetic (PBPK) model plus
more robustepidemiological datawill change [regulatory]
decisions in 1992." Paustenbach noted thepotential impor-
tance of information on short-term (peak) exposure to
benzene. Peak rather than cumulative exposure might be
the appropriate measure ofdose for benzene.
The default procedure for dose-response assessment
used by EPA and many other regulatory agencies is the
application of the linearized multistage model to admin-
istered dose cumulatively over a lifetime. This model was
intended for screening, based on oneplausiblemechanism
for the cancer process. All three case studies involve
biological information that may motivate replacement of
the default procedure with an alternative based on more
detailed understanding ofmechanism for that case-study
chemical. Key questions for the risk assessment are: Are
we measuring the dose in the right way for the biological
effect? (e.g., should we be using cumulative dose or peak
dose?)Dowehavethecorrectshapeforthedose-response
relationship? (e.g., should the relationship be linear
through zero or nonlinear, or no response at all until a
threshold has been exceeded?)
The implications of such departures for risk manage-
ment can be profound. The poster by Cox and Ricci
provides anexample. Theypropose acubicrelationshipfor
benzene dose-response. With a cubic relationship, risk
drops much more quickly than with a linear model as one
goes from occupational levels to the levels of benzene in
ambient air. Would we then conclude that 50-ppb levels of
benzene are acceptable, as opposed to the levels of10-37
ppt that Goldstein and Paustenbach cited, assuming a
linear model? What would be the implications of a cubic
dose-responserelationshipfordecisions onthereformula-
tion ofgasoline? While benzene levels ofless than 1% are
being contemplated for California, Europe continues to
use gasoline with even higher benzene levels than in the
U.S. Howaredecisions ontheappropriatebenzene content
ofgasoline going to be made? Will U.S. regulatory agen-
cies continue to use cumulative lifetime-dose and low-dose
linearityforbenzene? Departures fromthese defaultswill
need to be supported by mechanistic information. Given
the potential for altering the multibillion-dollar decisions
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on gasoline reformulation, is an appropriate amount of
mechanistic research now underway on benzene? The
magnitude ofthe risk management decision suggests that
the research strategy should be more aggressive.
Risk Characterization
It is clear that we need to do more to treat uncertainty
explicitly and to improve upon single-number body counts
as the input to risk management. I will defend EPA's
defaults as appropriateforscreening, butthey canbecome
highly inappropriate for chemicals for which we have
developed an understanding of pharmacokinetics and
mechanism ofaction. We have the example ofthe male rat
kidney tumors involvingthe a-2,-globulin mechanism, and
formaldehyde and butadiene are emerging as examples
where mechanistic understanding may support departure
from default regulatory assumptions. Perhaps in a few
years, we mayhave achieved amechanistic understanding
of benzene that will support departure from the default
assumptions. Even if we can make a lot of progress on
mechanistic understanding, uncertainties will remain. It
willbeimportanttoexplaintothepublicthescientificbasis
for departing from the usual assumptions in cancer risk
assessment.
Regulatory Decisions as a Context for
Valuing Research
While commending progress on the case studies, I also
notethattheyrepresentsubstantial amounts ofmoneyand
time. It took more than 10 years and millions ofresearch
dollars from initiation of research on the 0x-2u-globulin
mechanismtothe EPARiskAssessment Forumdocument
that Imogene Rogers described. But the improvement in
thedecision seemsto meclearlyworththetime and money.
Consider what it might have cost if a risk estimate based
on the bioassay data had been the basis for decisions to
impose tight controls on all U.S. gas pumps and on-board
vapor control systems for fuel systems on cars.
The advances inbiologyhave opened newopportunities,
and I believe thereis astrong case forvigorouslypursuing
these opportunities, even ifthey are expensive. For exam-
ple, the stem cells for the human blood-forming system
have been transplanted into mice, providing an excellent
vehicle for leukemia research. Such mice could be used to
study the mechanism by which benzene causes human
leukemia. Perhaps by this or other new approaches we
might get a firm biological basis for understanding
whether the dose-response relationship for benzene-
induced leukemiaislinear, cubic as Cox and Ricci propose,
or threshold in character. If we could conclude and per-
suade others that there is no leukemia risk for benzene
exposures below 50 ppb, we might save billions in refining
costs for reformulated fuels.
I do notwantto conclude on the optimistic notethat our
problems will be solved by scientific breakthroughs. Much
ofthetimethescientificresearchraisesasmanyquestions
as it answers, and anticipated breakthroughs prove elu-
sive. Research may tell us that some subportion of the
populationreallyis athighriskfrom exposure to gasoline,
its components, or reformulated fuels. Then the savings
from research will be valued in improvements to public
health.
Conclusion
We should conduct risk assessment iteratively and
share the data openly. This meeting and last year's expo-
suremeetingseemlike anexcellentwaytoproceed. Indus-
try has money and access to technical skills. Regulatory
agencies have amandate to develop understanding and to
implement measures needed to protect health. The public
and its leaders need to have trust that the science is
reliable and that they can trust the regulatory agencies to
do their job properly. Rather than have the regulatory
agencies and the regulated industry in an antagonistic
relationship, we should promote cooperation to obtain
better science and to overcome public mistrust and fear.
This last objective will require a continuing effort over a
long period.
We are making progress. The example of the at-2u-
globulin mechanism for the male rat kidney tumor shows
that industry and regulators can cooperate on the
research and implementation ofrisk assessmentadvances
based on improved mechanistic understanding. Further-
more,themechanisticresearchhasbeencomplementedby
large-scale epidemiological investigations to determine if
an excess ofkidney tumors and other forms ofcancer are
appearing in groups with high exposure to gasoline. Both
types ofresearch have significantly enhanced our ability
to assess the risk to human health posed by exposure to
gasoline.
This symposium has brought together a large and
distinguishedgroupofpeoplefromindustry, academicand
research institutions, and state and Federal regulatory
agencies. Reflecting on the discussions we have had over
the past 4 days, I believe this meeting reflects important
accomplishments. We are making progress in improving
the science, and we are making progress in translating
these improvements into the risk assessments and the
decisions on risk management for gasoline, its compo-
nents, andalternativefuels.Thisprogressshouldcontinue,
and we must continue our efforts to communicate an
understanding of the science to the wider audience-all
those concerned with the risk management decisions
regarding gasoline, its components, and its substitutes.
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